SBMF.F Stock Overview
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Sino Biopharmaceutical Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.38 |
| 52 Week High | HK$0.54 |
| 52 Week Low | HK$0.32 |
| Beta | 0.52 |
| 1 Month Change | 5.63% |
| 3 Month Change | n/a |
| 1 Year Change | -31.64% |
| 3 Year Change | -62.10% |
| 5 Year Change | -59.71% |
| Change since IPO | 3.46% |
Recent News & Updates
Recent updates
Shareholder Returns
| SBMF.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.6% | -2.2% | -3.7% |
| 1Y | -31.6% | 11.6% | 20.5% |
Return vs Industry: SBMF.F underperformed the US Pharmaceuticals industry which returned 11.7% over the past year.
Return vs Market: SBMF.F underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| SBMF.F volatility | |
|---|---|
| SBMF.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SBMF.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SBMF.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 25,806 | Eric S. Y. Tse | www.sinobiopharm.com |
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People’s Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines comprising Qingkeshu tablets, Focus V capsules, Annike injection, and Anyue capsules; liver disease medicines, including Tianqing ganmei injection and Runzhong dispersible tablets; and respiratory system medicines, such as Tianqing suchang suspension for inhalation and Tianyun for injection.
Sino Biopharmaceutical Limited Fundamentals Summary
| SBMF.F fundamental statistics | |
|---|---|
| Market cap | US$5.76b |
| Earnings (TTM) | US$255.17m |
| Revenue (TTM) | US$3.62b |
22.6x
P/E Ratio1.6x
P/S RatioIs SBMF.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SBMF.F income statement (TTM) | |
|---|---|
| Revenue | CN¥26.20b |
| Cost of Revenue | CN¥4.99b |
| Gross Profit | CN¥21.21b |
| Other Expenses | CN¥19.36b |
| Earnings | CN¥1.85b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.10 |
| Gross Margin | 80.95% |
| Net Profit Margin | 7.05% |
| Debt/Equity Ratio | 32.0% |
How did SBMF.F perform over the long term?
See historical performance and comparison